You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. GENETIC CYTOLOGY FOR SURVEILLANCE OF RECURRENT BLADDER CANCER

    SBC: PAPGENE, INC.            Topic: NCI

    This proposal details the development of UroSeqS as a genetic cytology test to extend the utility of routinely collected urine specimens to the detection of recurrent bladder cancer UroSeqS is a genetic cytology assay that achieves sensitivity and specificity through identifying DNA mutations causative of cancer from routinely collected clinical specimens An innovative approach is used toanalyz ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. A Yeast based Immunotherapy against Clostridium difficile Infection

    SBC: FZATA INC            Topic: NIAID

    Abstract Antibacterial resistance is a global public health crisis Antibiotic resistant Clostridium difficile is responsible for more than deaths in US each year and the infection represents an urgent threat to public health worldwide Of most concern is that the incidence of C difficile infection CDI and disease severity is rapidly increasing in recent years due to the emergence of hy ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Strategies to Improve Production of a Full Length Native HIV Env Spike

    SBC: CODEX BIOSOLUTIONS            Topic: R

    Project Summary Production of HIV envelope protein Env trimeric gp cleaved to gp gp for clinical studies is a critical objective for vaccine development Its conformational plasticity which allows it to adopt multiple conformational states important for function often makes its expression and purification very difficult Our recent work shows a route for overcoming this probl ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Serotype independent therapeutic vaccine for Streptococcus pneumoniae

    SBC: Integrated Biotherapeutics, Inc.            Topic: R

    In the era of growing antibiotic resistancelife threatening infections with several bacterial pathogens are cause for major concernApproved vaccines exist only for a handful of bacterial pathogensEven when a vaccine is available invasive bacterial diseases can occur due to lack of serotype coveragepoor vaccine response among vaccinated populationsor because many simply don t get vaccinatedThusinno ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Enhancing cytarabine efficacy in leukemia through CDK inhibition

    SBC: SENEX BIOTECHNOLOGY, INC.            Topic: 102

    Acute myeloid leukemia AML is the most common acute leukemia in adults with new cases annually in the US A deoxycytidine nucleoside analog Cytarabine AraC is the principal chemotherapeutic agent used in AML AraC containing chemotherapeutic regimens induce complete remission in of newly diagnosed AML patients but a substantial minority of leukemias is intrinsically resistant t ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Development and Validation of a Collaborative Web-Based Quantitative Imaging and Dosimetry System for Radiopharmaceutical Therapy

    SBC: RADIOPHARMACEUTICAL IMAGING AND DOSIMETRY, LLC            Topic: NCI

    Radiopharmaceutical therapyRPTis an emerging cancer treatment that delivers radiation directly to cancer cellsThe recent FDA approval ofRa Xofigotmfor resistant metastatic prostate cancer and its commercial success provides an example of the therapeutic and commercial potential of this modalityIn additiondrug companies have large libraries of targets and targeting moleculesProgress in chelators an ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Novel injectable resiquimod formulation for treatment of metastatic cancers

    SBC: Curebiotech, Inc.            Topic: NCI

    PROJECT SUMMARY Malignant melanoma is one of the most aggressive types of skin cancer causing a large majority of skin cancer related deaths worldwide Recently there have been staggering breakthroughs with the advent of drugs that act on checkpoint inhibitors These are paradigm shifting immunotherapeutic agents not only for melanoma but for cancers in general because they harness the bodyan ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer

    SBC: A&G PHARMACEUTICAL, INC.            Topic: NCI

    Significance Despite decreases in the overall number of new breast cancer BC cases reported in the US annually there are still about BC deaths annually from metastatic breast cancer MBC Thus the ability to monitor MBC is important to determine disease status and therapy response While the gold standard imaging is expensive time consuming and slow to detect disease response o ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. CRISPR Cas Systems Delivered by Targeted Nanoparticles to Eradicate Herpesvirus Pathogens

    SBC: Theragnostic Technologies Inc.            Topic: NIAID

    Abstract Herpesviruses are chronic pathogens that infect for life there is no cure years since the discovery of the first tumor virus the herpesvirus Epstein Barr virus EBV there exist no specific antivirals for EBV during its latency phase and there are no vaccines The same holds true for most of the other eight human herpesviruses This proposal aims to develop novel tools to eradicat ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. A Nitric Oxide Polymer Platform for the Prevention and Treatment of Infected Wounds

    SBC: IFYBER LLC            Topic: NIAID

    This proposed SBIR research effort will lay the foundation for commercializing a new class of biomaterial for the prevention and treatment of infected skin wounds thereby enhancing patient health through improved patient outcome and reduced patient morbidity Specifically we will focus on evaluating and developing a biomaterial comprised of a nitric oxide NO releasing based on a commonly used ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government